Targeting NRP1 in cancer therapy involves several strategies, including the use of monoclonal antibodies [2], small molecule inhibitors [13], and peptide-based therapeutics designed to block its interaction with ligands and co-receptors [5,14]. The gene discussed is NRP1; the disease is cancer.